iBio (IBIO) Stock Rockets On COVID-19 Vaccine Advancement

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) has been a leading contender in the race to develop a coronavirus vaccine. The companyw as one of the first to announce that it was working on a vaccine and is by far one of the most advanced.

The stock has seen tremendous gains since it announced that it was working to develop a vaccine for COVID-19, and those gains are continuing today. In fact, the stock is up more than 20% after announcing advancements made in its vaccine program. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Pops On COVID-19 Vaccine Advancement

In the press release, iBio said that immunization studies are beginning at Texas A&M University System laboratories. In particular, the immunization studies center around IBIO-200, the company’s SARS-CoV-2 Virus-Like Particle program.

The company said that the work is being performed as part of the Master Joint Development Agreement established between IBIO and TAMUS in 2016.

In the release, the company reminded investors that it created proprietary VLP candidates in just a few weeks using its FastPharming System. From there, scientists deployed the plant-based expression platform’s rapid production capabilities to deliver VLPs suitable for development just weeks after the original design.

In a statement, Tom Isett, Co-Chairman and CEO at IBIO, had the following to offer:

This next stage of work on IBIO-200 is critically important as we seek to quickly enter the clinic with one of our VLP candidates. As we optimize our choice of adjuvants with both VLP types we have developed, we are fortunate to have a strong relationship with TAMUS that allows us to rapidly bring their deep insight into the pathogenesis of coronaviruses and experience with vaccine development to the task.

Why Investors Are So Excited

There’s good reason for all of the excitement here. First and foremost, there are several companies out there that are working to create vaccines. However, very few have clinic-ready candidates. iBio is one of these companies.

Beyond that, the company has several strategic advantages. With its FastPharming Facility, IBIO has the ability to rapidly produce the vaccine in mass quantities. In the face of a pandemic, speed is everything, and speed is on the company’s side.

Beyond that, the company teamed up with CC Pharming. This Chinese company opens the doors in terms of international commercialization. Not to mention, CC Pharming has already developed a vaccine for SARS-coronavirus, a cousin virus to the one at the center of today’s pandemic.

With the combined strategic advantages of IBIO and CC Pharming, it’s hard to imagine that this team wouldn’t play a key role in vaccinating the world against COVID-19. All in all, this could prove to be a massive opportunity!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.